Programmed cell death 1 (PD-1) and its ligand (PD-L1) are key physiologic suppressors of the cytotoxic immune reaction. However, to date, the combination of PD1/PD-L1 expression and tumor-infiltrating lymphocytes (TILs) and antigen-presenting cells has been only minimally reported in breast carcinoma, in particular in relation to HER2-positive cases. The goal of this study was to evaluate both cellular tumoral immune reaction and PD-L1/PD1 distribution in HER2-positive cases, as well as any associations with clinical outcome using conventional chemotherapy combined with HER2 blocking. Multicolor immunohistochemical multiplex assays simultaneously demonstrating PD1, PD-L1, and CD8 or PD-L1, CD3, and CD163 were performed on tissue microarrays (TMA) representing 216 pretreatment cases of HER2-positive invasive breast carcinoma. PD-L1 expression was identified in 38 cases (18%), including 12 cases (6%) with PD-L1 labeling of tumor cells and 26 cases (12%) with PD-L1 labeling of immune cells only. Ten of 12 cases with PD-L1 staining of tumor cells showed staining of associated immune cells as well.
| INTRODUCTION
Approximately 15%-20% of breast cancers demonstrate HER2 (ERBB2) gene amplification and/or protein overexpression. [1] [2] [3] Anti-HER2 therapy, such as trastuzumab, is effective against HER2 + tumors and has been incorporated within standard therapy of
HER2
+ tumors over the past 15 years. 4, 5 However, both primary and secondary resistances to anti-HER2 agents have been observed in up to 50% of HER2-postive patients. [6] [7] [8] One key immune response modifier is the PD-1 (programmed cell rates in a variety of tumor types. [9] [10] [11] [12] [13] [14] Limited data have been reported on the expression of PD-L1 in tumor cells and/or immune cells in breast cancer, but preliminary reports are divergent. [15] [16] [17] [18] There has been no study to date investigating PD-L1 expression in a pure cohort of HER2-positive breast carcinoma, although published studies have included patients with HER2-positive breast carcinoma in their cohorts. In general, there is agreement that PD-L1 is expressed in higher percentage of HER2-positive and triple-negative breast cancer (TNBC) cases as compared to other breast cancer types. [17] [18] [19] Recently, the combination of PD-L1 and tumor-infiltrating lymphocytes (TILs) has been investigated in TNBC, and the reported findings confirm the importance of examining both PD-L1 and TILs for clinical outcome prediction. 17, 20, 21 In the current study, we evaluated PD-L1 and a set of other relevant immune markers in relation to their association with clinical outcome in a series of HER2-positive cases. 
| MATERIALS AND METHODS

| Patients and specimens
| Tissue microarrays (TMAs)
A tumor block representative of primary resected tumor specimen was collected from each case through Tissue Archive Services. A pair of TMAs representative of each tumor was constructed with core size of 1.5 mm at our pathology core facility.
| Multicolor multiplex immunohistochemistry and assessment of checkpoint immune system
Multicolor multiplex immunohistochemical assays capable of demonstrating colocalization of PD-L1 with either PD1 and CD8 or CD163
and CD3 were performed on TMA sections according to manufacturers' protocol. The antibodies used were as follow: for PD-L1
clone SP263, rabbit, Ventana; for PD1 clone NAT105, mouse, Ventana; for CD8 clone MRQ26, mouse, Ventana; for CD163 clone SP57, rabbit, Ventana; for CD3 clone 2GV6, rabbit, Ventana. The 
| Statistical analyses
All data were analyzed using SAS version 9. test, except that age and tumor size were assessed using Wilcoxon test. Overall survival (OS) was calculated from the date of diagnosis to death from any cause or the date of last follow-up. Patients who were still alive were censored at the last follow-up. Survival curves were estimated using the method of Kaplan-Meier. For the univariate analysis, the association between OS and categorical variables is studied using log-rank test. The association between OS and age was studied using Cox regression model. P values <0.05 were considered statistically significant. The median survival has not been reached overall and in many of the subgroups as well due to the extended survival time of breast cancer patients managed with current modalities. In particular, several subgroups (eg, patients with
have not yet suffered a single event (death).
Therefore, a multivariate analysis with Cox regression model could not yet be carried out.
| RESULTS
| Patient characteristics
A total of 216 surgically resected FFPE primary HER2-positive breast carcinomas were included in the study. There was a median followup of 73 months (range 7-162 months) and a median age at diagnosis of 53 years (range 27-88 years). The majority of tumors (63%)
were grade 3, while 47% of patients had lymph node metastasis (Table 1) . PD-L1 ICs. However, PD1 was expressed in many fewer cases (6 or only 3%) ( Table 1) .
|
Next, we examined the association between PD-L1 expression and clinical/pathologic characteristics. PD-L1 expression was positively associated with higher Nottingham grade, negative ER and PR status, and the absence of lymph node metastasis. Furthermore, PD-L1 expression was positively associated with high levels of intratumoral/peritumoral CD8 + and peritumoral CD163 + cells, but not intratumoral CD163 + cells (Table 2 ).
In addition, we compared PD-L1 TC + cases (n = 12) with only PD-L1 IC + cases (n = 26 (Table 4) . Kaplan-Meier curves of OS were also plotted with several significantly associated factors including PD-L1, intratumoral CD8 + cells lymph node status, and T stages, as shown in Figure 3 .
Median survival has not been reached for many subgroups; therefore, a multivariate analysis with Cox regression model was not performed.
| DISCUSSION
To our knowledge, this is the first large study focusing solely on HER2-positive breast carcinomas to assess both tumor cell and stromal immune cell expression of PD-L1 together with other immune biomarkers (PD1, CD8, CD3, and CD163). In our cohort, PD-L1 expression, high CD8 + cell levels, the absence of lymph node metastasis, and lower T stages were all significantly correlated with better OS.
The frequency of PD-L1 expression has not previously been | 915 studies differed from that used in our analysis (SP263 from Ventana).
The cutoff for positive PD-L1 expression in tumor cells was chosen at ≥1% for all previous studies, with the exception of one study which used 5% 22 ; and the cutoff for positive PD-L1 expression in immune cells was 5% except for one study which used 1%. 23 In our earlier pilot study 24 with a different cohort of 123 HER2-positive breast cancers, which consisted of larger samplings (whole section slides), a higher percentage of PD-L1 + cases was encountered (up to 17% in tumor cells and 55% in immune cells). This disparity between our two studies is likely due to a higher likelihood of detecting positive cellularity in much larger samples, as the distribution of PD-L1
staining is often somewhat focal or multifocal rather than uniform. In our current study, the PD-L1/PD1 expression was examined in relation to markers for T cells and antigen-presenting cells by using two multicolor multiplex immunohistochemical assays capable of demonstrating colocalization of PD-L1 and PD1 with other cell typespecific markers (CD8, CD3, and CD163). This novel technique has allowed us to accurately localize PD-L1 expression in tumor cells and/or immune cells and PD1 in immune cells, as well to assess CD8 + or CD3 + T-lymphocytes and CD163 + antigen-presenting cells.
T A B L E 3 Comparison between 12 cases with PDL1 expression in tumor cells and 26 cases with PD-L1 expression in immune cells only
PD-L1-TC
Our observations confirm the presence of antigen-presenting cells in the vast majority of cases with PD-L1 expression (Tables 1 and 3 ).
This supports recent experimental evidence indicating a pivotal role for macrophage amplification of the PD-L1 immune checkpoint system. 25 The low frequency of PD1 staining among immune cells probably relates to the assay method. It has been shown by flow cytometry studies that CD8-positive T cells express PD1 in cell surface distribution, and that this is much weaker expression than that The greatest limitation of this study is perhaps the use of TMAs, which may result in a relatively lower percentage of PD-L1-positive cases in our cohort as compared to previously published studies 19, 22 and to our own recent, yet unpublished study in which PD-L1 expression was examined on the basis of whole section slides and PD-L1 expression was identified in up to 17% of HER2-positive breast cancer cases in tumor cells and 55% in immune cells. 24 It has been shown that PD-L1 is expressed variably within and around tumor cellularity, and thus, TMAs may not be representative, raising the possibility of false-negative results. A strength of the study is its relatively large sample size (216 cases). A second limitation is this study's reliance on a single PD-L1 antibody clone (SP263; Roche Ventana). There are multiple anti-PD-L1 antibodies available commercially; the cutoff values and PD-L1 expressing cells are different among these antibodies. It will be interesting to examine PD-L1 expression in these same specimens using different anti-PD-L1 antibodies. Additionally, the clinical data associated with our cohort were limited to overall survival only. Distal metastasis or local recurrence data were not available for analysis. In our future study, it would be interesting to investigate PD-L1/PD1's association with distal metastasis or local recurrence to further understand their clinical impact.
In conclusion, our data indicate that both primary immune reaction with CD8 + cells and PD-L1 expression are predictive of outcome for HER2-positive breast cancer managed with standard therapy. Supported by other studies as well, these findings raise hope that such evaluation may play an important role in predicting response to immune checkpoint therapy. 17, 20, 21 
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